Menu
Menu
What’s the biggest challenge facing the cannabis industry right now, and how are you and/or your company addressing it?
The biggest challenge is regulatory inconsistency, where drafted laws and proposed policy changes create uncertainty for patients, adult-use consumers and businesses alike. In Germany, new proposed restrictions on medical cannabis, based on unfounded assumptions, risk undermining patient access and stifling innovation. At Bloomwell Group, we’re addressing this by advocating for patient-centered reform and building scalable, compliant business models that can adapt to change.
We’re also providing transparent data that counters the claims of policymakers that patients are abusing the progressive measures of the Medical Cannabis Act via digital access and prescription deliveries. What we’ve found from a Bloomwell Group survey of nearly 3,900 patients, conducted alongside a DocCheck survey of 500 physicians, is that only 13% of patients requesting cannabis received a prescription. This counters claims of patient abuse, and rather suggests patients need to turn to telemedicine and specialists due to their primary care providers failing to meet their needs or lack of expertise. Another data point on that front is that almost two-thirds rated their doctors’ expertise in medical cannabis as “poor” or “unsatisfactory.” And instead of cannabis, 68.7% of patients were prescribed alternative medications, including 56.2% for narcotics (e.g., fentanyl for chronic pain).
Our surveys and research have also found that almost half of the cannabis patients in Germany do not have access to a brick-and-mortar pharmacy specializing in cannabis treatment within a 10-kilometer radius. Alongside their convenience, speediness and seamless feedback via chat functions, this is yet another reason that telehealth services are a necessity.
Where do you see the most exciting opportunity for growth and innovation in cannabis?
The most exciting opportunity still lies in the vast medical potential of cannabis, as the plant continues to move from niche to mainstream healthcare. As Germany’s market matures and more countries liberalize access, innovation in formulations, delivery methods, and digital health integration will accelerate. We’re just getting started, and the demand and need for cannabis as medicine is massive! 94 percent of cannabis users in Germany reported they take cannabis for at least one medical or health reason, according to a representative survey we conducted last year, but at the time, most of those people were still acquiring cannabis from the illicit market. So, as you can see, there’s still a ton of opportunity for public education, medical market expansion and increased access. That’s why at Bloomwell Group, we’re investing in telemedicine, patient education, and data-driven care to personalize treatment and empower consumers to access the treatment they need.
What’s one piece of advice you would give to someone looking to break into the cannabis industry?
Be patient, persistent, and purpose-driven. Cannabis is not a shortcut to quick profits. It’s really an industry built on resilience, science, and social progress. Success comes from understanding regulation, prioritizing compliance, and staying true to the mission of improving lives. My advice: enter with a long-term mindset and surround yourself with experts who can bridge business, medicine, and policy. That’s what we’re doing in Germany, as it’s clear that the medical market has not only seen rapid growth, but has yet to reach its full potential.
What is the most important thing you have learned from your experiences in the cannabis industry?
I’ve learned that progress in cannabis is rarely linear. Even as public opinion and science advance, policy can lag behind. The key is to remain adaptable. We need to balance innovation with compliance while keeping patients at the center. This industry demands collaboration across regulators, doctors, pharmacies, wholesalers and ancillary service providers to drive meaningful change. It’s a reminder that perseverance and integrity are as vital as strategy.
What do you want your legacy to be as it relates to the cannabis industry?
I want to help normalize cannabis as a legitimate, accessible part of modern healthcare by championing medical research and data, alongside technological innovations. My goal is for Bloomwell Group to stand as a model of how patient care and responsible digital access that maximizes convenience can all coexist. Fortunately, we’re on our way to doing just that. Bloomwell launched the very first telemedicine platform for medical. cannabis in Germany and has been a changemaker for hundreds of thousands of patients to date. If we can make cannabis treatment as accepted as any other therapy, while inspiring a new generation of European cannabis leaders, that would be the legacy I’m proud to leave.